Skip to main content
. 2018 Jun 20;32(6):543–558. doi: 10.1007/s40263-018-0530-8

Fig. 1.

Fig. 1

Disability outcomes measures used in phase III relapsing multiple sclerosis or RRMS trials (n = 16). Includes unpublished trials and trials published from 2012 onwards (with the exception of the DEFINE and CONFIRM trials, which are included in the review by Lavery et al. [20]). EDSS Expanded Disability Status Scale, FDA freedom from disease activity, MSFC Multiple Sclerosis Functional Composite, MSIS Multiple Sclerosis Impact Scale, NEDA no evidence of disease activity, SF-36 Medical Outcomes Study Short-Form (36-item) Health Survey, RRMS relapsing-remitting multiple sclerosis